This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 23/5/769    most recent 01.ATV.0000068646.76823.AEv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luan, Z. Articles by Newby, A. C. Search for Related Content PubMed PubMed Citation Articles by Luan, Z. Articles by Newby, A. C. Related Collections Coumarins CPR and emergency cardiac care

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:769.)
© 2003 American Heart Association, Inc.

Vascular Biology

Statins Inhibit Secretion of Metalloproteinases-1, -2, -3, and -9 From Vascular Smooth Muscle Cells and Macrophages

Zhaoxia Luan^*; Alex J. Chase^*; Andrew C. Newby

From Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol, UK.

Correspondence to Professor Andrew Newby, Bristol Heart Institute, Bristol Royal Infirmary, Bristol BS2 8HW, UK. E-mail A.Newby{at}bris.ac.uk

Objective— Production of several metalloproteinases (MMPs) from smooth muscle cells (SMCs) and macrophages causes matrix destruction and atherosclerotic plaque instability. Statins, which inhibit HMG-CoA reductase and hence cholesterol and isoprenoid synthesis, stabilize plaques. We investigated whether statins inhibit MMP secretion from SMCs and macrophages.

Methods and Results— We used human saphenous vein and rabbit aortic SMC and foamy macrophages from cholesterol-fed rabbits. Cerivastatin (50 nmol/L) inhibited inducible MMP-1, -3, and -9 secretion from human SMC by 52±19%, 71±18%, and 73±17%, respectively (P<0.01, n=3). Similar dose-related effects of cerivastatin (50 to 500 nmol/L), simvastatin (1 to 20 µmol/L), and lovastatin (5 to 20 µmol/L) were consistent with their relative potencies against HMG-CoA reductase. Statins also inhibited inducible MMP-1, -3, and -9 and constitutive MMP-2 secretion but not TIMP-1 or -2 secretion from rabbit SMC. Statins also dose-dependently inhibited MMP-1, -3, and -9 secretion from rabbit foam cells; cerivastatin (50 nmol/L) inhibited by 68±18%, 74±14%, and 74±14%, respectively (P<0.01, n=4). Statins similarly decreased collagenolytic, caseinolytic, and gelatinolytic activity. Mevalonate and geranylgeranylpyrophosphate but not squalene reversed the effects, showing dependence on isoprenoid, not cholesterol depletion. Statins did not affect MMP mRNA levels.

Conclusions— Statins inhibit secretion of a several MMPs from both SMCs and macrophages, which could therefore contribute to their plaque-stabilizing effects.

Key Words: statins • metalloproteinases • atherosclerosis • plaque instability • isoprenoids

This article has been cited by other articles:

				K. I. Paraskevas, C. D. Liapis, G. Hamilton, and D. P. Mikhailidis Are Statins an Option in the Management of Abdominal Aortic Aneurysms? Vascular and Endovascular Surgery, May 1, 2008; 42(2): 128 - 134. [Abstract] [PDF]

				T. Aoki, H. Kataoka, R. Ishibashi, K. Nozaki, and N. Hashimoto Simvastatin Suppresses the Progression of Experimentally Induced Cerebral Aneurysms in Rats Stroke, April 1, 2008; 39(4): 1276 - 1285. [Abstract] [Full Text] [PDF]

				S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]

				A. J. White, S. J. Duffy, A. S. Walton, J. F. Ng, G. E. Rice, S. Mukherjee, J. A. Shaw, G. L. Jennings, A. M. Dart, and B. A. Kingwell Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease Cardiovasc Res, September 1, 2007; 75(4): 813 - 820. [Abstract] [Full Text] [PDF]

				N. Ferri, G. Colombo, C. Ferrandi, E. W. Raines, B. Levkau, and A. Corsini Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1043 - 1049. [Abstract] [Full Text] [PDF]

				S. Tartakover-Matalon, N. Cherepnin, M. Kuchuk, L. Drucker, I. Kenis, A. Fishman, M. Pomeranz, and M. Lishner Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression Hum. Reprod., April 1, 2007; 22(4): 1161 - 1167. [Abstract] [Full Text] [PDF]

				E. Acheampong, Z. Parveen, A. Mengistu, N. Ngoubilly, B. Wigdahl, A. S. Lossinsky, R. J. Pomerantz, and M. Mukhtar Cholesterol-Depleting Statin Drugs Protect Postmitotically Differentiated Human Neurons against Ethanol- and Human Immunodeficiency Virus Type 1-Induced Oxidative Stress In Vitro J. Virol., February 1, 2007; 81(3): 1492 - 1501. [Abstract] [Full Text] [PDF]

				J. Herrmann, L. O. Lerman, D. Mukhopadhyay, C. Napoli, and A. Lerman Angiogenesis in Atherogenesis Arterioscler. Thromb. Vasc. Biol., September 1, 2006; 26(9): 1948 - 1957. [Abstract] [Full Text] [PDF]

				V. Liebe, M. Brueckmann, M. Borggrefe, and J. J. Kaden Statin therapy of calcific aortic stenosis: hype or hope? Eur. Heart J., April 1, 2006; 27(7): 773 - 778. [Abstract] [Full Text] [PDF]

				J. P.G. Sluijter, D. P.V. de Kleijn, and G. Pasterkamp Vascular remodeling and protease inhibition-bench to bedside Cardiovasc Res, February 15, 2006; 69(3): 595 - 603. [Abstract] [Full Text] [PDF]

				K. K. Ray and C. P. Cannon The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1425 - 1433. [Abstract] [Full Text] [PDF]

				I. Kenis, S. Tartakover-Matalon, N. Cherepnin, L. Drucker, A. Fishman, M. Pomeranz, and M. Lishner Simvastatin has deleterious effects on human first trimester placental explants Hum. Reprod., October 1, 2005; 20(10): 2866 - 2872. [Abstract] [Full Text] [PDF]

				N. P. Kadoglou, S. S. Daskalopoulou, D. Perrea, and C. D. Liapis Matrix Metalloproteinases and Diabetic Vascular Complications Angiology, March 1, 2005; 56(2): 173 - 189. [Abstract] [PDF]

				A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF]

				P E Lazzerini, P L Capecchi, F Nerucci, A Fioravanti, F Chellini, M Piccini, S Bisogno, R Marcolongo, and F Laghi Pasini Simvastatin reduces MMP-3 level in interleukin 1{beta} stimulated human chondrocyte culture Ann Rheum Dis, July 1, 2004; 63(7): 867 - 869. [Abstract] [Full Text] [PDF]

				P. E. Szmitko, C.-H. Wang, R. D. Weisel, G. A. Jeffries, T. J. Anderson, and S. Verma Biomarkers of Vascular Disease Linking Inflammation to Endothelial Activation: Part II Circulation, October 28, 2003; 108(17): 2041 - 2048. [Full Text] [PDF]

				C. B Jones, D. C Sane, and D. M Herrington Matrix metalloproteinases: A review of their structure and role in acute coronary syndrome Cardiovasc Res, October 1, 2003; 59(4): 812 - 823. [Abstract] [Full Text] [PDF]

				H. N. Hodis, W. J. Mack, S. P. Azen, R. A. Lobo, D. Shoupe, P. R. Mahrer, D. P. Faxon, L. Cashin-Hemphill, M. E. Sanmarco, W. J. French, et al. Hormone Therapy and the Progression of Coronary-Artery Atherosclerosis in Postmenopausal Women N. Engl. J. Med., August 7, 2003; 349(6): 535 - 545. [Abstract] [Full Text] [PDF]